Literature DB >> 15613801

[Reappraisal of HBV genotypes and clinical significance in Koreans using MALDI-TOF mass spectrometry].

Jung Min Lee1, Sang Hoon Ahn, Hye Young Chang, Ji Eun Shin, Do Young Kim, Myoung Ki Sim, Sun Pyo Hong, Hyun Jae Chung, Soo Ok Kim, Kwang Hyub Han, Chae Yoon Chon, Young Myoung Moon.   

Abstract

BACKGROUND/AIMS: Recent studies have shown that the genotype of hepatitis B virus (HBV) may correlate with the disease natural history and treatment outcome. However, several of these studies used low sensitivity assays in a small number of patients, and this has precluded an accurate evaluation of Korean HBV genotypes. We analyzed Korean HBV genotypes in a large population by employing a new technology, restriction fragment mass polymorphism (RFMP) using MALDI-TOF mass spectrometry, in a sensitive and specific manner.
METHODS: Between February 1995 and December 2003, a total of 475 patients with chronic HBV infection were enrolled. The assay is based on the mass measurement of oligonucleotides having genotypic variations of the S gene. Clinical features including the virologic status and disease progression were also evaluated.
RESULTS: The median age of the total patients was 35.5 years. Out of 475 patients, there were 162 (34.1%) inactive carriers, 172 (36.2%) had chronic hepatitis, 77 (16.2%) had liver cirrhosis and 64 (13.5%) had hepatocellular carcinoma (HCC). There were 454 patients (95.6%) with genotype C, 4 patients (0.8%) with genotype A, 16 patients (3.4%) with the mixed A and C genotype [7 patients (1.4%) with A<C versus 9 patients (2.0%) with C>A], and 1 patient (0.2%) with B genotype. Comparing genotype A and C, genotype A patients were all inactive carriers without HCC, whereas genotype C patients included those with chronic hepatitis, liver cirrhosis and HCC.
CONCLUSIONS: HBV genotype C is highly prevalent in Korea. Although it is a small percentage, genotype A also exists and it seems to take a more benign clinical course than genotype C. Further studies are necessitated to assess the relationship between HBV genotypes and the various aspects of the diseases' clinical course.

Entities:  

Mesh:

Year:  2004        PMID: 15613801

Source DB:  PubMed          Journal:  Korean J Hepatol        ISSN: 1738-222X


  9 in total

Review 1.  KASL clinical practice guidelines: management of chronic hepatitis B.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2016-03-28

Review 2.  Clinical utility of complex mutations in the core promoter and proximal precore regions of the hepatitis B virus genome.

Authors:  Young Min Park
Journal:  World J Hepatol       Date:  2015-01-27

3.  KASL Clinical Practice Guidelines: Management of chronic hepatitis B.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2012-06-26

4.  Association between polymorphism of tumor necrosis factor-alpha promoter and response to lamivudine treatment in patients with chronic hepatitis B.

Authors:  Yong Kwang Park; Jung Min Lee; Do Young Kim; Hye Young Chang; Ja Kyung Kim; Chun Kyon Lee; Jun Yong Park; Sang Hoon Ahn; Kwan Sik Lee; Kwang Hyub Han
Journal:  Dig Dis Sci       Date:  2009-10-15       Impact factor: 3.199

5.  Clinical efficacy of a 24-months course of lamivudine therapy in patients with HBeAg negative chronic hepatitis B: a long-term prospective study.

Authors:  Yong Han Paik; Ja Kyung Kim; Do Young Kim; Jun Yong Park; Sang Hoon Ahn; Kwang-Hyub Han; Chae Yoon Chon; Kwan Sik Lee
Journal:  J Korean Med Sci       Date:  2010-05-24       Impact factor: 2.153

6.  High efficacy of adefovir and entecavir combination therapy in patients with nucleoside-refractory hepatitis B.

Authors:  Hee Bok Chae; Mee Jin Kim; Eui Geun Seo; Yong Hyeok Choi; Hee Seung Lee; Joung Ho Han; Soon Man Yoon; Seon Mee Park; Sei Jin Youn
Journal:  Korean J Hepatol       Date:  2012-03-22

7.  Virologic response and safety of tenofovir versus entecavir in treatment-naïve chronic Hepatitis B patients.

Authors:  Hyung Min Yu; So Young Kwon; Jiwan Kim; Hyun Ah Chung; Se Woong Kwon; Taek Gun Jeong; Sang Hee An; Gyung Won Jeong; Seon Ung Yun; Jae Ki Min; Jeong Han Kim; Won Hyeok Choe
Journal:  Saudi J Gastroenterol       Date:  2015 May-Jun       Impact factor: 2.485

8.  Long-term real-world entecavir therapy in treatment-naïve hepatitis B patients: base-line hepatitis B virus DNA and hepatitis B surface antigen levels predict virologic response.

Authors:  Ju-Yeon Cho; Won Sohn; Dong-Hyun Sinn; Geum-Youn Gwak; Yong-Han Paik; Moon Seok Choi; Kwang Cheol Koh; Seung Woon Paik; Byung Chul Yoo; Joon Hyeok Lee
Journal:  Korean J Intern Med       Date:  2016-11-04       Impact factor: 2.884

9.  Correlation between Results of Semi-Quantitative and Quantitative Tests for Hepatitis B Virus Surface Antigen among Patients Achieving Viral Suppression with Antiviral Treatment.

Authors:  Goh Eun Chung; Ju Yeon Kim; Hyunjae Shin; Ji Hoon Hong; Moon Haeng Hur; Heejin Cho; Min Kyung Park; Na Ryung Choi; Jihye Kim; Yun Bin Lee; Eun Ju Cho; Su Jong Yu; Yoon Jun Kim; Jung-Hwan Yoon; Jeong-Hoon Lee
Journal:  Diagnostics (Basel)       Date:  2022-07-20
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.